Pulling SEC filings + quote and writing the call…
Not at current levels — our verdict on REGENXBIO Inc. (RGNX) is HOLD (conviction 2 of 5): fairly priced on the filings; own it, don't chase it.
Speculative binary on AbbVie-partnered eye gene therapy; going-concern doubt and CRL/clinical holds cap it at a small catalyst bet, not a core holding.
We re-rate when the company’s filings change, never the chart. Every change lands on the Flip Side and is scored on the live track record.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 2, 2026, 11:43 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.